Abstract
Deregulated dynamics of the extracellular matrix (ECM) are one of the hallmarks of cancer. Studies on tumor mechanobiology are thus expected to provide an insight into the disease pathogenesis as well as potentially useful biomarkers. Type I collagen is among the major determinants of breast ECM structural and tensile properties, and collagen modifications during tumor evolution drive a number of disease-related processes favoring cancer progression and invasion. We investigated the use of 3D collagen-based scaffolds to identify the modifications induced by cancer cells on the mechanical and structural properties of the matrix, comparing cell lines from two breast tumor subtypes with different clinical aggressiveness. Orthotopic implantation was used to investigate the collagen content and architecture of in vivo breast tumors generated by the two cell lines. MDA-MB-231, which belongs to the aggressive basal-like subtype, increased scaffold stiffness and overexpressed the matrix-modifying enzyme, lysyl oxidase (LOX), whereas luminal A MCF-7 cells did not significantly alter the mechanical characteristics of extracellular collagen. This replicates the behavior of in vivo tumors generated by MDA-MB-231, characterized by a higher collagen content and higher LOX levels than MCF-7. When LOX activity was blocked, the ability of MDA-MB-231 to alter scaffold stiffness was impaired. Our model could constitute a relevant in vitro tool to reproduce and investigate the biomechanical interplay subsisting between cancer cells and the surrounding ECM and its impact on tumor phenotype and behavior.
Keywords: Cancer biomechanics, Collagen scaffolds, Breast tumors, Stiffness, Aggressive cells
Introduction
The extracellular matrix (ECM) has a vital role in the regulation of various biological pathways contributing to development, tissue homeostasis and diseases.5 ECM properties are modified in multiple pathological processes either as a cause or a result of the disease pathogenesis.5 In cancer, it is known that ECM remodeling is capable of fostering a number of tumor processes such as progression 24 and metastasis initiation.33 In particular, breast cancer has been defined as a disease of altered mechanobiology: matrix density, structure and stiffness, together with interstitial fluid pressure and flow, change during tumor evolution.13 As an example, the collagen matrix of breast cancer stroma is significantly stiffer and more linearized than in normal tissue, due to a progressive enzymatic crosslinking mediated by cancer cells.24 Linearized collagen fibers can substantially increase growth factor-dependent cell migration and directly promote tumor progression.24 In addition, altered mechanical signaling affects cell survival, motility, division, and differentiation.12,15,21 Investigations into these processes provided a new insight into breast cancer pathogenesis, leading to the identification of clinically useful biomarkers. It has been shown that an ECM gene signature can stratify breast cancer patients into subclasses that predict outcome.3 Furthermore, increased breast tumor density in mammography has proven to be significantly correlated with reduced progression-free survival in metastatic patients 14 and to be an excellent predictor of response to tamoxifen in the preventive setting.11
In vitro research offers several experimental methods and models to investigate the tumor mechanobiology.8 In particular, tridimensional (3D) biomimetic matrices provide the ideal tools to efficiently recapitulate tissue dimensionality and the biomechanical and physical cues of tumor ECM.19 A number of 3D systems have been used to investigate how cancer cells interact with the ECM, or to address the impact of mechanical signaling in diverse tumor phenotypes and behaviors.9,29,40 Collagen is a major component of the breast connective tissue and is a key determinant of its tensile properties34 and of the macroscopic deformability of mammary tumors16 that are characterized by increased collagen content and remodeling.35
In the present study we used a porous type I collagen scaffold to investigate the ability of breast cancer cells to produce alteration in the material mechanical characteristic. This biomimetic matrix, providing a physiological network in 3D, constitutes the model of choice to reproduce in vitro the cell–ECM interactions. Specifically, we assessed the modifications induced by cancer cells on the compressive stiffness of the scaffolds, comparing cell lines of two breast tumor subtypes characterized by different clinical aggressiveness and distinct ECM characteristics. The aim was to demonstrate whether this 3D model might offer a valid and informative tool to recapitulate and investigate the biomechanical interaction between cancer cells and the surrounding ECM.
Materials and Methods
In Vitro Experimental Model
Two different human breast cancer cell lines, MCF-7 and MDA-MB-231, were cultured for 10 days on 3D porous collagen scaffolds. MCF-7 cells belong to the luminal A subtype of breast cancer and are associated with weak in vitro invasiveness, whereas MDA-MB-231 belong to the basal-like subtype and are associated with an invasive behavior17 and the ability to colonize different sites (e.g. bone, liver, lung and brain) after intravenous injection.22 At the end of the culture time, the phenotypes of the two cell lines were characterized by morphological and molecular analyses, while the mechanical and structural properties of the scaffolds were tested to assess the modifications induced in the collagen matrix by either cell line (Fig. 1a).
Synthesis of the Porous Collagen Scaffolds
All chemicals were purchased from Sigma Aldrich (USA). The scaffolds were synthesized from type I bovine collagen, as described elsewhere.26 Briefly, a 1 wt% collagen suspension in acetate buffer (pH 3.5) was prepared. The collagen was then precipitated to pH 5.5 with NaOH 1 M. The collagen was then washed three times with deionized water and then crosslinked in an aqueous solution of 1,4-butanediol diglycidyl ether (BDDGE) (2.5 mM), for 24 h. Finally, the collagen was washed three times and casted in Teflon molds (9 mm in diameter) and freeze dried through an optimized freezing and heating ramp to obtain the desired pore size and porosity (from 25 to −25 °C and from −25 to 25 °C in 50 min, p = 0.20 mbar). The morphology of the scaffold was characterized by scanning electron microscopy (SEM) and the pore size determined by ImageJ (US National Institutes of Health); the swelling properties of the scaffold and overall porosity were determined through water and ethanol infiltration methods.26 Mean diameters were determined by caliper measurement. All analyses were performed on both control scaffolds and scaffolds after a 10-day culture with MCF-7 and MDA-MB-231 (after the decellularization step).
Cell Seeding and Culture
MCF-7 and MDA-MB-231 cell lines were obtained from the American Type Culture Collection (USA). All cells were maintained in DMEM medium supplemented with 10% fetal bovine serum, 1% penicillin–streptomycin and 1% glutamine (PAA, USA) at 37 °C in a 5% CO2 atmosphere. Each scaffold was placed in a 6-multiwell plate and seeded with 5 × 1012 cells by dropping 50 µL of the cell suspension on the scaffold. Cells were allowed to adhere for 1 h at 37 °C, after which 4 mL of culture medium were gently added to each well. After a 24-h incubation, all scaffolds were carefully removed and placed in a new 6-multiwell plate. Medium was replaced daily. Uncellularized control scaffolds were maintained in cell-free culture medium at the same temperature and humidity conditions.
Cell Quantification
The number of cells infiltrating the scaffold on day 10 was assessed by total DNA content quantification using the PicoGreen dsDNA assay (Invitrogen, Carlsbad, CA, USA). The total DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen, Duesseldorf, Germany) following the manufacturer’s instructions and 100 µL of DNA mixture were then added to 100 µL of PicoGreen reagent working solution. Fluorescence of the samples was measured with a microplate reader (FLUOstar OPTIMA BMG LABTECH, Ortenberg, Germany), with excitation and emission wavelengths of 480 and 520 nm, respectively. The total number of cells was determined using the conversion factor of 7.7 pg DNA/cell.
Histological Analysis
The collagen constructs were fixed in 10% neutral buffered formaldehyde and dehydrated in a graded series of ethanol. Samples were then embedded in paraffin, sliced at a thickness of 5 µm with a rotating microtome (Leica Biosystems, USA) and mounted on Superfrost Plus microslides (Thermo Fisher Scientific, USA). Hematoxylin and eosin (H&E) staining was performed to evaluate cell morphology and distribution in the scaffold matrix.
LOX Inhibition
The activity of LOX was blocked by the irreversible LOX inhibitor, β-aminopropionitrile (BAPN) (Sigma Aldrich).4,27,42 MDA-MB-231 cells within the scaffold were treated with 500 µM of BAPN 24 h after seeding. BAPN was administered on a daily basis until the end of the experiment. On day 10 the culture was stopped, cell proliferation with or without LOX inhibition was assessed by MTT assay, and the mechanical test was performed.
Scaffold Decellularization
The scaffolds were decellularized in 0.5% Triton X-100 for 1 h at room temperature and then washed three times in phosphate saline buffer (PBS). Uncellularized scaffolds were exposed to the same decellularization process to ensure that the experimental conditions did not contribute to scaffold mechanical properties. Decellularization was confirmed by the absence of MTT metabolization. The remaining DNA content of the decellularized scaffolds was assessed as follows: total DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, Germany) following the manufacturer’s instructions and quantified with a NanoDrop ND-1000 spectrophotometer.
Mechanical Testing
We developed a prototype loading device to apply a state of unconfined uniaxial compression to the collagen scaffolds (Fig. 1b). This in-house built instrument consisted of a base support with a cylindrical hole (diameter 30 mm, depth 0.5 mm) designed to lodge the scaffold specimen, and a cylindrical piston (diameter 10 mm) to indent the specimen with known force values. The applied stress (σ, in kPa) could then be computed by dividing the applied force by the cross section of the specimen. The applied force consisted of a pre-load of 0.09 N (corresponding to a pre-stress of 1.41 kPa), which was held constant for 30 s; the full load of 0.38 Newton (corresponding to 5.97 kPa) was then constantly applied for 30 s. Such holding times were sufficient for the visco-elastic time-dependent deformation to reach an equilibrium. The piston was equipped with a dial gauge (Borletti, Milan, Italy) to measure the piston displacement while the specimen was compressed. The consequent strain (ε, dimensionless) was computed by dividing the measured piston displacement by the height of the specimen. The dial gauge had a resolution of 0.002 mm (corresponding to a resolution of 0.1% for the strain). The stiffness (compressive modulus, in kPa) of the collagen scaffold was computed as the ratio between the increment of stress and increment of strain from the pre-load to the full load values.2 The specimens were tested in air immediately after having been removed from the PBS where they were soaked. The compressive modulus of collagen scaffolds decellularized after a 10-day culture with MCF-7 or MDA-MB-231 was compared with that of uncellularized scaffolds. Five specimens of each type were tested. Each specimen was tested 10 times to improve the quality of the measurement. The compressive modulus of each specimen was computed as the average of the 10 repeated measurements.
Microscopy Analysis
The collagen scaffolds were imaged by SEM and Laser Confocal Microscopy. For SEM imaging, samples were washed in 0.1 M sodium cacodylate buffer pH 7.4 and fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 for 2 h at 4 °C. Samples were then dehydrated in a graded series of ethanol, desiccated and sputter-coated with platinum. Images were acquired with a Nova NanoSEM (FEI, USA). For confocal imaging, cells were washed in 1% PBS and fixed with 4% paraformaldehyde for 20 min at room temperature. Images where taken with an A1 laser confocal microscope (Nikon Corporation, Japan).
Quantitative Real-Time Reverse Transcription-PCR (qRT-PCR)
Total mRNA was isolated using TRIzol Reagent (Invitrogen, USA) following the manufacturer’s instructions. Five hundred nanograms of RNA were reverse-transcribed using the iScript cDNA Synthesis Kit (BioRad, USA). The final mixture was incubated at 25 °C for 5 min, 42 °C for 20 min, 47 °C for 20 min, 50 °C for 15 min, and finally a 85 °C for 5 min. Real Time-PCR was performed in a 7500 Real-Time PCR System (Applied Biosystems, USA) using the TaqMan universal assay mix (Applied Biosystems). Amplification was performed in a final volume of 20 µL containing 2× Gene Expression Master Mix (Applied Biosystems) and 2 µL of cDNA. The reaction mixtures were all subjected to 2 min at 50 °C, 10 min at 95 °C followed by 40 PCR cycles at 95 °C for 15 s and 60 °C for 1 min. The stably expressed endogenous β-actin and HPRT were used as reference genes. Three target markers were analyzed: vimentin (VIM), E-cadherin (CDH1) and lysyl oxidase (LOX). The amount of these transcripts was normalized to the endogenous reference genes and expressed as n-fold mRNA levels relative to a calibrator using the comparative threshold cycle (Ct) value method (ΔΔCt). The calibrator used for all the analyses was a mix of the RNA extracted from MCF7 and MDA-MB-231 in standard monolayer cultures.
MTT Assay
Cell survival in MDA-MB-231 treated with the LOX inhibitor BAPN was assessed by MTT assay. Briefly, the scaffolds were incubated for 2 h at 37 °C in 0.5 mg/mL of MTT solution (Sigma Aldrich). After solubilization in acidic isopropanol, the absorbance was read at 550 nm. Cell survival was determined by comparing the average absorbance of cells in the absence or presence of BAPN treatment.
Xenograft Study
To establish orthotopic breast tumors, MCF-7-Luc2 and MDA-MB-231-Luc2 cells, both marked with a luciferase probe, were suspended in 100 µL of matrigel (BD, Franklin Lakes, NJ, USA) at a concentration of 5 × 1012 cells and orthotopically injected into the right mammary fat pad of 8 week-old female immunodeficient nu/nu nude mice. Tumor growth was followed by in vivo bioluminescence imaging and caliper measurement every 2–3 days after the injection. After 4 weeks, tumors were resected and embedded in Optimal Cutting Temperature (OCT) compound and cryo-sectioned.
Collagen Staining
Trichrome staining and Picrosirius red were performed on the OCT-embedded frozen tissues to study the tumor collagen matrix, and on collagen scaffold sections. Trichrome staining (Abcam) was performed according to manufacturer’s instructions. For Picrosirius red the frozen sections were stained with 0.1% (Direct Red 80) (Sigma Aldrich) sirius red in saturated aqueous solution of picric acid and counterstained with Weigert’s hematoxylin. The RGB images were analyzed by ImageJ.
Statistical Analysis
At least three independent experiments were performed. Data are presented as mean ± standard error (SE), with n indicating the number of replicates. For in vitro and in vivo data, differences between groups were assessed by a two-tailed Student’s t test and accepted as significant at p < 0.05.
Results
Collagen Scaffold Properties
The collagen scaffolds had a mean diameter of 9 ± 0.5 mm (Fig. 2a) and a mean thickness of 2 mm. The size of the pores ranged from 150 to 300 μm, with a mean pore size of 197 ± 25 μm (Fig. 2b and 2c). Collagen fibers showed a high degree of structural assembling and preserved their typical D-bands (arrowhead) (Fig. 2d) a characteristic axial D-periodic (67 nm) morphology derived from the self-assembly of single collagen molecules. The scaffolds displayed a mean porosity percentage of 87.8 ± 4.1 (Fig. 2e).
Collagen Remodeling in Breast Xenograft Tumors
Orthotopic implantation of MCF-7 and MDA-MB-231 in female immunodeficient mice was performed to investigate the collagen content and architecture in the ECM of in vivo breast tumors. After 4 weeks both cell lines had developed detectable mammary tumors. Bioluminescence imaging and caliper measurement showed that MCF-7 grew considerably slower than MDA-MB-231 displaying a mean tumor volume of 70 ± 15 µm3 compared to 388 ± 68 µm3 of MDA-MB-231 (Fig. 3a). Trichrome staining of resected tumor sections revealed a higher presence of thick collagen fibers in MDA-MB-231 orthotopic tumors compared to those generated by MCF-7 (Fig. 3b). Moreover, quantification of the collagen percentage in Picrosirius red stained sections showed that MDA-MB-231 tumors displayed a significantly higher collagen content than that of MCF-7 ones (p = 0.0005) (Fig. 3c). Finally, the in vivo expression of the matrix crosslinking enzyme LOX was markedly higher for MDA-MB-231 than for MCF-7 (Fig. 3d).
Interaction of Breast Cancer Cells with the Extracellular Collagen Matrix
When cultured on collagen scaffolds, the two cell lines generated tissue-like structures and maintained their distinctive features: MCF-7 displayed an epithelial-like morphology with a tightly cohesive cobblestone appearance, while MDA-MB-231 showed a mesenchymal phenotype with lower cell-to-cell contact and a spindle appearance (Fig. 4a). Both cell lines proliferated within the scaffold, and on day 10 the number of cells reached about 9 × 106 for MCF-7 and 9.8 × 106 for MDA-MB-231 (Fig. 4b). Gene expression analysis showed that MCF-7 had a high level of E-cadherin expression but low vimentin, while MDA-MB-231 showed lower levels of E-cadherin and a high vimentin expression (Fig. 4c). MDA-MB-231 proved capable of internalizing collagen: confocal images of the scaffold matrix revealed the presence of blue collagen spots in the scaffolds cellularized with MDA-MB-231. These signals were not detectable in empty scaffolds or in the presence of MCF-7 cells (Fig. 4d). The collagen spots showed an intracellular localization that was further highlighted in images processed with ImageJ software (Fig. 4e).
Assessment of the Prototytpe Loading Device Repeatability
Preliminary tests were performed on MDA-MB-231-cultured scaffolds to evaluate the repeatability of the measures obtained with the prototype loading device. The instrument and setting conditions exhibited good consistency that resulted in homogeneous dispersion of the different measures, as well as of the average values of technical replicates (Fig. 5a). The intra-assay coefficient of variation was 10.7%, which was deemed sufficient for our purposes. No conditioning effect was detected when the same specimen was repeatedly loaded.
Alteration of the Compressive Stiffness of Collagen Scaffolds by Invasive Breast Cancer Cells
We investigated the effect of MCF-7 and MDA-MB-231 on the stiffness properties of collagen scaffolds by comparing the compressive modulus of uncellularized samples with that of samples decellularized after 10 days of culture with either cell line. The efficacy of the decellularization process was confirmed by MTT metabolization, which was virtually absent in decellularized samples (Fig. 5b). Furthermore, the DNA content decreased from 175.9 ± 16.46 ng/µL for cellularized scaffolds to 11.1 ± 4.9 ng/µL for decellularized scaffolds (Fig. 5c). MCF-7 did not significantly affect the mechanical properties of the scaffolds: uncellularized samples displayed an average compressive modulus of 47.1 ± 1.8 kPa, while samples decellularized after MCF-7 culture showed an average compressive modulus of 48.9 ± 1.3 kPa. Conversely, MDA-MB-231 cells produced a significant (p = 0.038) increase in the scaffold stiffness: uncellularized samples displayed an average compressive modulus of 46.9 ± 2.7 kPa, while samples decellularized after MDA-MB-231 culture had an average compressive modulus of 57.9 ± 3.6 kPa (Fig. 5d). Scaffold compressive modulus increased by 23% after MDA-MB-231 cell culture, in sharp contrast to the increase observed after culture with MCF-7 (<5%) (Fig. 5e). Finally, MDA-MB-231 within the collagen scaffolds showed around a 1000-fold higher expression level of LOX than MCF-7 (Fig. 5f).
Collagen Scaffold Remodeling by Breast Cancer Cells
After 10 days’ culture within the scaffold, MCF-7 and MDA-MB-231 cells altered the structural micro and macro characteristics of the collagen matrix. A significant decrease in the scaffold swelling property was produced by both cell lines with respect to uncellularized samples (p = 0.022 for MCF-7 and p = 0.042 for MDA-MB-231) (Fig. 6a). The average porosity was also reduced, albeit not significantly (Fig. 6b). Both cell lines decreased the mean pore area of the scaffold, but the decrease produced by MDA-MB-231 was markedly higher compared to that of MCF-7 (p = 0.002 for MDA-MB-231) (Fig. 6c). SEM analysis showed the presence of a rough and irregular matrix over the scaffold surface after MCF-7 and MDA-MB-231 culture, whereas uncellularized samples displayed a smooth and regular surface (Fig. 6d).
Collagen quantification by Picrosirius red staining showed that the two cell lines did not increase the collagen content of the scaffold with respect to uncellularized samples (Fig. 6e). This result suggests that matrix proteins other than collagen were deposited by the two cell lines.
The scaffold matrix architecture differed markedly between uncellularized samples and samples cultured with MCF-7 or MDA-MB-231, as detected by Masson’s trichrome staining. In particular, the matrix appeared more organized, densely packed and with linear collagen fibers (arrowhead) in the presence of MDA-MB-231, whereas uncellularized scaffolds and scaffolds cultured with MCF-7 displayed a more dispersed and disorganized matrix (Fig. 7a).
Impairment of MDA-MB-231 Cell Ability to Increase Collagen Stiffness by LOX Inhibition
The survival percentage of BAPN-treated MDA-MB-231 cells was similar to that of untreated controls, indicating that BAPN did not affect proliferation (Fig. 7b). In the presence of LOX inhibition the ability of MDA-MB-231 cells to increase the stiffness of the collagen scaffold was reduced: uncellularized samples displayed an average compressive modulus of 55.5 ± 2.6 kPa, while samples decellularized after MDA-MB-231 culture with BAPN treatment showed an average compressive modulus of 58.1 ± 5.2 kPa (Fig. 7c). Scaffold compressive modulus increased by 8.9% with LOX inhibition compared to 23% without LOX inhibition (Fig. 7d).
Discussion
A dynamic mechanical interaction subsists between cancer cells and the surrounding ECM environment and governs essential tumor processes.23 Thus, investigating the cancer mechanobiology represents a great opportunity to achieve a better understanding of the disease and to identify novel therapeutic targets or prognostic biomarkers. Three-dimensional scaffolds that enable the tuning of matrix microstructure, stiffness and composition offer a unique in vitro experimental model to study the effects exerted by these biochemical and physical parameters on the behavior of cancer cells.20,24,36 In this study we have utilized type I collagen scaffolds as an in vitro 3D biomimetic model to study the cell–ECM interaction occurring between either MDA-MB-231 or MCF-7 breast cancer cells, that are known to have different clinical aggressiveness.17 Towards this end, our collagen scaffolds were the model of choice, as it (i) resembled the main component of the ECM; (ii) can be easily fabricated; (iii) and each feature can be tuned (e.g. structure, pore size, porosity, wettability, degradation).26
Mechanical signaling from the ECM influence different tumor phenotypes,29,37,38 and the mechanical characteristics of tumors and tumor cells are predictive of the disease clinical behavior.31,41 We first showed that in vivo orthotopic tumors generated by MDA-MB-231 cells, belonging to the more aggressive basal-like subtype, were characterized by elevated collagen content and high expression of LOX compared to tumors generated by MCF-7. Increased LOX levels and tumor stiffness have been associated with progression7,24,28,30 and local invasion via oriented cell migration on aligned collagen fibers.32 Moreover, the elevated expression of fibrillar collagens has been linked to the invasive and aggressive behavior of breast tumors.43 Similar changes have been described by Acerbi and colleagues in specific subtypes of breast cancers. The authors found that the stroma at the invasive region of basal-like and Her-2 tumor subtypes was the most heterogeneous and the stiffest when compared to the less aggressive luminal A and B subtypes.1 The two cell lines within the scaffolds preserved their specific phenotypes. Weakly aggressive MCF-7 cells displayed an epithelial-like morphology and a high expression of the E-cadherin epithelial marker. Conversely, MDA-MB-231 showed an infiltrating and mesenchymal phenotype with lower E-cadherin expression and high levels of vimentin. Loss of E-cadherin is a key step in the epithelial to mesenchymal transition (EMT) process and has been implicated in cancer progression and metastasis, while vimentin expression drives a number of cellular processes including motility.25 Using an originally-developed prototype instrument to assess the compression-dependent viscoelastic properties of collagen scaffolds, we were able to show that MDA-MB-231 produced a significant increase in macroscopic stiffness of our in vitro biomimetic model. While both cell lines induced a decrease in the scaffold swelling property and pore area, probably as a result of new matrix deposition, MDA-MB-231 cells proved capable of remodeling the scaffold architecture, producing a more organized and densely packed matrix. This cell line expressed high levels of the collagen-crosslinking enzyme LOX both in vivo and in the collagen scaffolds. Conversely, MCF-7 expressed lower levels of LOX and did not significantly modify scaffold stiffness or architecture. Collagen crosslinking is related to its stiffness properties 6 and is, to a large extent, enzymatically catalyzed by the lysyl oxidase family.30 When LOX activity was blocked, the ability of MDA-MB-231 to alter scaffold stiffness was impaired, providing a causal correlation between LOX-mediated collagen crosslinking and the observed increase in stiffness. Finally, MDA-MB-231 seemed to have the ability of collagen internalization which constitutes an important mechanism for ECM turnover and remodeling.10 This process has been correlated with breast cancer progression and is mediated by the uPARAP/Endo180 receptor, expressed in basal-like breast tumor cells.39 Recent findings have also shown that EMT is able to enhance the ability of cancer cells to internalize collagen.18
Overall this work provides evidence that cancer cells belonging to the aggressive basal-like subtype of breast tumors display a greater ability to modify the surrounding ECM and in particular are able to alter the mechanical properties of extracellular collagen. Although our scaffold did not reproduce all the physiological characteristics of the breast ECM (i.e. it displayed a larger pore size), the cells showed a strong interaction with this matrix. Furthermore, the increase observed in the scaffold stiffness is consistent with the collagen characteristics in in vivo tumors and with previous findings on the ECM of basal-like breast cancers.1
These observations demonstrate that 3D collagen scaffolds might constitute a relevant and informative experimental model to address the mechanobiology of cell–ECM interaction. Moreover, due to the abundance of functional groups, collagen can be functionalized with further components of the ECM 37 and the properties of the matrix tuned to achieve different mechanical characteristics in order to investigate their role in the tumor phenotypes and behavior.
Acknowledgements
The authors wish to thank Marco Palanca for his contribution to designing and fine-tuning the compression device. They also thank Silvia Bellissimo for editorial assistance.
Conflicts of Interest
Chiara Liverani, Laura Mercatali, Luca Cristofolini, Emanuele Giordano, Silvia Minardi, Giovanna Della Porta, Alessandro De Vita, Giacomo Miserocchi, Chiara Spadazzi, Ennio Tasciotti, Dino Amadori and Toni Ibrahim have no conflicts of interest to declare.
Research involving animals
All experimental animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Houston Methodist Research Institute (HMRI) protocol number AUP 0614-0033.
References
- 1.Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr. Biol. (Camb.) 2015;7:1120–1134. doi: 10.1039/C5IB00040H. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Beer F, Russell Johnsnon E, Jr, DeWolf JT, Mazurek DF. Mechanics of Materials. 6. New York: McGraw-Hill Publ.; 2011. [Google Scholar]
- 3.Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2008;214:357–367. doi: 10.1002/path.2278. [DOI] [PubMed] [Google Scholar]
- 4.Bondareva A, Downey CM, Ayres F, Liu W, Boyd SK, Hallgrimsson B, Jirik FR. The lysyl oxidase inhibitor, β-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS ONE. 2009;4:e5620. doi: 10.1371/journal.pone.0005620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 2014;15:786–801. doi: 10.1038/nrm3904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Buehler MJ. Nature designs tough collagen: explaining the nanostructure of collagen fibrils. Proc. Natl. Acad. Sci. USA. 2006;103:12285–12290. doi: 10.1073/pnas.0603216103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat. Rev. Cancer. 2009;9:108–122. doi: 10.1038/nrc2544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Carey SP, D’Alfonso TM, Shin SJ, Reinhart-King CA. Mechanobiology of tumor invasion: engineering meets oncology. Crit. Rev. Oncol. Hematol. 2012;83:170–183. doi: 10.1016/j.critrevonc.2011.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cassereau L, Miroshnikova YA, Ou G, Lakins J, Weaver VM. A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype. J. Biotechnol. 2015;193:66–69. doi: 10.1016/j.jbiotec.2014.11.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, Molinolo AA, Behrendt N, Nielsen BS, Bugge TH. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol. 2005;169:977–985. doi: 10.1083/jcb.200411153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J. Natl. Cancer Inst. 2011;103:744–752. doi: 10.1093/jnci/djr079. [DOI] [PubMed] [Google Scholar]
- 12.Du Fort CC, Paszek MJ, Weaver VM. Balancing forces: architectural control of mechanotransduction. Nat. Rev. Mol. Cell Biol. 2011;12:308–319. doi: 10.1038/nrm3112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J. Surg. Oncol. 2011;103:468–474. doi: 10.1002/jso.21709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Elsamany S, Alzahrani A, Elkhalik SA, Elemam O, Rawah E, Farooq MU, Almatrafi M, Olayan FK. Prognostic value of mammographic breast density in patients with metastatic breast cancer. Med. Oncol. 2014;31:96. doi: 10.1007/s12032-014-0096-3. [DOI] [PubMed] [Google Scholar]
- 15.Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126:677–689. doi: 10.1016/j.cell.2006.06.044. [DOI] [PubMed] [Google Scholar]
- 16.Fenner J, Stacer AC, Winterroth F, Johnson TD, Luker KE, Luker GD. Macroscopic stiffness of breast tumors predicts metastasis. Sci. Rep. 2014;4:5512. doi: 10.1038/srep05512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215. doi: 10.1186/bcr2889. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, Isacke CM. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS ONE. 2010;5:e9808. doi: 10.1371/journal.pone.0009808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Infanger DW, Lynch ME, Fischbach C. Engineered culture models for studies of tumor–microenvironment interactions. Annu. Rev. Biomed. Eng. 2013;15:29–53. doi: 10.1146/annurev-bioeng-071811-150028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Insua-Rodríguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv. Drug Deliv. Rev. 2016;97:41–55. doi: 10.1016/j.addr.2015.12.017. [DOI] [PubMed] [Google Scholar]
- 21.Janmey PA, Miller RT. Mechanisms of mechanical signaling in development and disease. J. Cell Sci. 2011;124:9–18. doi: 10.1242/jcs.071001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–549. doi: 10.1016/S1535-6108(03)00132-6. [DOI] [PubMed] [Google Scholar]
- 23.Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009;28:113–127. doi: 10.1007/s10555-008-9173-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891–906. doi: 10.1016/j.cell.2009.10.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24:1838–1851. doi: 10.1096/fj.09-151639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Minardi S, Sandri M, Martinez JO, Yazdi IK, Liu X, Ferrari M, Weiner BK, Tampieri A, Tasciotti E. Multiscale patterning of a biomimetic scaffold integrated with composite microspheres. Small. 2014;10:3943–3953. doi: 10.1002/smll.201401211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Nilsson M, Adamo H, Bergh A, HalinBergström S. Inhibition of lysyl oxidase and lysyl oxidase-like enzymes has tumour-promoting and tumour-suppressing roles in experimental prostate cancer. Sci. Rep. 2016;6:19. doi: 10.1038/s41598-016-0018-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast. 2013;22(Suppl. 2):S66–S72. doi: 10.1016/j.breast.2013.07.012. [DOI] [PubMed] [Google Scholar]
- 29.Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8:241–254. doi: 10.1016/j.ccr.2005.08.010. [DOI] [PubMed] [Google Scholar]
- 30.Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer—a prospect. J. Cell. Biochem. 2007;101:1338–1354. doi: 10.1002/jcb.21371. [DOI] [PubMed] [Google Scholar]
- 31.Plodinec M, Loparic M, Monnier CA, Obermann EC, Zanetti-Dallenbach R, Oertle P, Hyotyla JT, Aebi U, Bentires-Alj M, Lim RY, Schoenenberger CA. The nanomechanical signature of breast cancer. Nat. Nanotechnol. 2012;7:757–765. doi: 10.1038/nnano.2012.167. [DOI] [PubMed] [Google Scholar]
- 32.Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006;4:38. doi: 10.1186/1741-7015-4-38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev Cancer. 2009;9:285–293. doi: 10.1038/nrc2621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Roeder BA, Kokini K, Sturgis JE, Robinson JP, Voytik-Harbin SL. Tensile mechanical properties of three-dimensional type I collagen extracellular matrices with varied microstructure. J. Biomech. Eng. 2002;124:214–222. doi: 10.1115/1.1449904. [DOI] [PubMed] [Google Scholar]
- 35.Schedin P, Keely JP. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb. Perspect. Biol. 2011;3:a003228. doi: 10.1101/cshperspect.a003228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Shawn PC, Kraning-Rush CM, Williams RM, Reinhart-King CA. Biophysical control of invasive tumor cell behavior by extracellular matrix microarchitecture. Biomaterials. 2012;33:4157–4165. doi: 10.1016/j.biomaterials.2012.02.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Tan Y, Tajik A, Chen J, Jia Q, Chowdhury F, Wang L, Chen J, Zhang S, Hong Y, Yi H, Wu DC, Zhang Y, Wei F, Poh YC, Seong J, Singh R, Lin LJ, Doğanay S, Li Y, Jia H, Ha T, Wang Y, Huang B, Wang N. Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression. Nat. Commun. 2014;5:4619. doi: 10.1038/ncomms5619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ulrich TA, de Juan Pardo EM, Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res. 2009;69:4167–4174. doi: 10.1158/0008-5472.CAN-08-4859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wienke D, Davies GC, Johnson DA, Sturge J, Lambros MB, Savage K, Elsheikh SE, Green AR, Ellis IO, Robertson D, Reis-Filho JS, Isacke CM. The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res. 2007;67:10230–10240. doi: 10.1158/0008-5472.CAN-06-3496. [DOI] [PubMed] [Google Scholar]
- 40.Wozniak MA, Keely PJ. Use of three-dimensional collagen gels to study mechanotransduction in T47D breast epithelial cells. Biol. Proced. Online. 2005;7:144–161. doi: 10.1251/bpo112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Xu W, Mezencev R, Kim B, Wang L, McDonald J, Sulchek T. Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS ONE. 2012;7:e46609. doi: 10.1371/journal.pone.0046609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Yang X, Li S, Li W, Chen J, Xiao X, Wang Y, Yan G, Chen L. Inactivation of lysyl oxidase by β-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells. Oncol. Rep. 2013;29:541–548. doi: 10.3892/or.2012.2146. [DOI] [PubMed] [Google Scholar]
- 43.Zaman MH, Trapani LM, Sieminski AL, Mackellar D, Gong H, Kamm RD, Wells A, Lauffenburger DA, Matsudaira P. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc. Natl. Acad. Sci. USA. 2006;103:10889–10894. doi: 10.1073/pnas.0604460103. [DOI] [PMC free article] [PubMed] [Google Scholar]